title: Modified periodontal risk assessment score: long-term predictive value of treatment outcomes. A retrospective study.
abstract: OBJECTIVE
  The aim of this study was to evaluate the long-term clinical predictive value of the periodontal risk assessment diagram surface (PRAS) score and the influence of patient compliance on the treatment outcomes.
  
  
  METHODS
  Thirty subjects suffering from periodontitis were re-examined 6-12 years after the initial diagnosis and periodontal treatments. The baseline PRAS score was calculated from the initial clinical and radiograph records. Patients were then classified into a low-to-moderate (0-20) or a high-risk group (>20). Patients who did not attend any supportive periodontal therapy were classified into a non-compliant group. PRAS and compliance were correlated to the mean tooth loss (TL)/year and the mean variation in the number of periodontal pockets with a probing depth (PPD) >4 mm.
  
  
  RESULTS
  TL was 0.11 for the low-to-moderate-risk group and 0.26 for the high-risk group (p<0.05); PPD number reduction was 2.57 and 2.17, respectively, and bleeding on probing reduction was 6.7% and 23.3%, respectively. Comparing the compliance groups, the PPD number reduction was 3.39 in the compliant group and 1.40 in the non-compliant group (p<0.05).
  
  
  CONCLUSIONS
  This study showed the reliability of PRAS in evaluating long-term TL and patient susceptibility to periodontal disease. Our data confirmed the positive influence of patient compliance on periodontal treatment outcomes.
authors.affiliation: Department of Periodontology, Dental Faculty, University of Strasbourg, Strasbourg, France.
authors.forename: Matthieu
authors.initials: M
authors.lastname: Leininger
authors.forename: Henri
authors.initials: H
authors.lastname: Tenenbaum
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Davideau
mesh_terms: D010520:Aggressive Periodontitis / Q000150:complications / Q000276:immunology / Q000628:therapy*; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D055113:Chronic Periodontitis / Q000150:complications / Q000276:immunology / Q000628:therapy*; D012534:Dental Scaling; D004198:Disease Susceptibility; D005260:Female; D006801:Humans; D016014:Linear Models; D008137:Longitudinal Studies; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D010349:Patient Compliance; D010512:Periodontal Index; D011379:Prognosis; D012189:Retrospective Studies; D018570:Risk Assessment / Q000379:methods; D015572:Spiramycin / Q000627:therapeutic use; D016388:Tooth Loss / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D000891:Anti-Infective Agents, Local; D008795:Metronidazole; D015572:Spiramycin